Jan H. Schornagel

Health-Related Quality-of-Life Assessments and Patient-Physician Communication

Symone Detmar, Martin J. Muller, Jan H. Schornagel et al. · JAMA · 2002 · 1K citations

Medicine, Oncology, Health Communication +16

Randomized Phase III Trial of High–Dose-Intensity Methotrexate, Vinblastine, Doxorubicin, and Cisplatin (MVAC) Chemotherapy and Recombinant Human Granulocyte Colony-Stimulating Factor Versus Classic MVAC in Advanced Urothelial Tract Tumors: European Organization for Research and Treatment of Cancer Protocol No. 30924

Cora N. Sternberg, P.H.M. de Mulder, Jan H. Schornagel et al. · Journal of Clinical Oncology · 2001 · 628 citations

Medicine, Oncology, Pharmacology +13

Seven year update of an EORTC phase III trial of high-dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumours

Cora N. Sternberg, PHM de Mulder, Jan H. Schornagel et al. · European Journal of Cancer · 2005 · 545 citations

Medicine, Oncology, Urology +9

How Are You Feeling? Who Wants To Know? Patients’ and Oncologists’ Preferences for Discussing Health-Related Quality-of-Life Issues

Symone Detmar, Neil K. Aaronson, Lieke Wever et al. · Journal of Clinical Oncology · 2000 · 348 citations

Medicine, Oncology, Medical Oncology +16

Randomized comparison of cisplatin, methotrexate, bleomycin and vincristine (CABO) versus cisplatin and 5-fluorouracil (CF) versus cisplatin (C) in recurrent or metastatic squamous cell carcinoma of the head and neck

M. Clavel, Jan B. Vermorken, F. Cognetti et al. · Annals of Oncology · 1994 · 278 citations · Full text

Medicine, Oncology, Pharmacology +12